Renal toxicity of mitomycin-C.

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Background:

• Mitomycin-C is an antineoplastic agent used in cancer treatment.
• Renal toxicity is a known, but not fully understood, side effect of mitomycin-C therapy.

Observation:

• Four patients treated with mitomycin-C exhibited significant renal toxicity.
• Renal impairment was associated with cumulative doses exceeding 60 mg of mitomycin-C.

Findings:

• Pathological findings revealed glomerular and vascular damage.
• These changes resemble microangiopathic hemolytic anemia, suggesting a thrombotic microangiopathy.
• Endothelial damage and coagulation activation may occur, especially with combination chemotherapy.

Implications:

• Early detection of renal impairment is crucial for intervention.
• Withdrawing mitomycin-C may halt or reverse kidney damage progression.
• This highlights the importance of monitoring renal function in patients receiving mitomycin-C.